A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

654

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: tafasitamab
DRUG: rituximab
DRUG: lenalidomide
DRUG: placebo

Sponsor

Incyte Corporation